TLTFF aims to raise C$3M to C$5M via units including shares and warrants exercisable until May 20, 2031.
Theralase Technologies launched a brokered private placement of units priced at C$0.24 each, targeting gross proceeds of C$3M to C$5M. Each unit consists of one common share and one warrant, exercisable at C$0.32 per share through May 20, 2031.
Research Capital is acting as the sole agent and bookrunner for the offering. The agent holds an option to increase the offering size by up to 15%, depending on demand.
The placement aims to fund ongoing operations and strategic initiatives, though specific use of proceeds was not detailed in the announcement.